BEIJING: AstraZeneca’s antibody beverage for COVID-19 prevention has been cleared use with a medical tourism zone in China’s southern province of Hainan ahead of nationwide approval, local press said on Tuesday (Jul 5).
China enables early use of new medical products in the special zone as part of several preferential guidelines granted to the area to promote medical solutions to visitors from both home plus abroad.
Hainan Daily, backed by provincial Communist Celebration authority, reported that a shipment worth twenty one. 98 million yuan (US$3. 28 million) of AstraZeneca’s antibody-based therapy Evusheld has completed procedures on local customs because special imports.
The drug has been authorised in many regions including the United States, the United Kingdom and European Union with regard to preventing infections in people whose immune system is actually weak to respond to vaccines.
AstraZeneca did not immediately answer a Reuters request comment.
Various other Western products however to be cleared with regard to national use but currently available in Hainan’s Boao Lecheng Worldwide Medical Tourism Pilot Zone include Novartis’ breast cancer drug Piqray and Gilead’s yeast infection medicine AmBisome.
Merck’s blockbuster cancer treatment Keytruda had also been eliminated for import towards the zone in 2016 before it was accepted nationally two years afterwards.
Read more upon: https://www.channelnewsasia.com/asia/china-allows-astrazenecas-covid-19-preventive-drug-southern-city-2792376